LLY LLY
Eli Lilly Price Target Raised by Daiwa Securities Amid Strong Performance
Daiwa Securities Group revised its price objective for Eli Lilly. Accelerating operational performance and strong demand for core products drive the...
Eli Lilly Stock Declines Amid Broader Market Gains and Valuation Debates
Eli Lilly (LLY) shares fell 1.77% to $1017.72 on February 18, 2026, underperforming the broader market as investors reassess the company's valuation following...
Eli Lilly Combination Therapy Achieves Superior Skin Clearance and Weight Loss in Phase 3b Psoriasis Trial
Eli Lilly and Company reported positive topline results from the TOGETHER-PsO Phase 3b clinical trial. The study evaluated Zepbound (tirzepatide) combined with...
Eli Lilly and CSL Ink Licensing Deal for Anti-Inflammatory Drug
Eli Lilly and Company signed an exclusive licensing agreement with Australian biopharma firm CSL. The agreement covers the monoclonal antibody candidate...
Eli Lilly to Invest $1 Billion in India Hub to Scale Global Supply and Launch New Drugs
Eli Lilly and Company will invest $1 billion to establish India as a central hub for its global supply chain. The pharmaceutical giant will utilize local...
Eli Lilly’s Retevmo Becomes First RET Inhibitor to Succeed in Phase 3 Early-Stage Lung Cancer Trial
Eli Lilly and Company reported positive topline results from its Phase 3 LIBRETTO-432 clinical trial evaluating Retevmo (selpercatinib). The study tested the...
Eli Lilly Stockpiles $1.5 Billion of Experimental Weight-Loss Drug Ahead of FDA Ruling
Eli Lilly (LLY) has built a $1.5 billion inventory of its experimental oral obesity drug, orforglipron, ahead of an expected 2026 FDA decision to aggressively...
Eli Lilly in after-hours trading at $1042.00 amid analyst upgrades and stockpile news
Eli Lilly shares rose 2.34% to close at $1038.96 after Freedom Capital Markets upgraded the stock to Buy with a $1200 price target. The upgrade highlights the...
🟢 LLY is trading 3% up today following Freedom Capital upgrade and Orna acquisition
LLY is trading at $1045.74 (+3.01%) today following a Freedom Capital upgrade to Buy and the company's $2.4B acquisition of Orna Therapeutics. • Freedom...
Eli Lilly Secures China Approval for Mirikizumab, Tapping World’s Second-Largest Pharma Market
Eli Lilly and Company received approval from Chinese regulators on Wednesday for its drug, mirikizumab. The authorization covers the treatment of adults with...
Eli Lilly Upgraded to Buy Following $2.4 Billion Acquisition of Orna Therapeutics
Freedom Capital analyst Ilya Zubkov has upgraded Eli Lilly to Buy from Hold with a price target of $1,200, citing strong growth momentum. The upgrade follows a...
Eli Lilly Diversifies Beyond GLP-1s with $10.9 Billion in New Biotech Deals
Eli Lilly aggressively expanded its clinical pipeline through two major deals totaling nearly $11 billion, focusing on circular RNA and immunology. Despite...
Eli Lilly Acquires Orna Therapeutics for $2.4 Billion to Advance Circular RNA Pipeline
Eli Lilly announced it is acquiring biotechnology firm Orna Therapeutics for $2.4 billion in cash, securing a key technology platform to strengthen its...
Eli Lilly and Innovent Ink Seventh Deal to Fast-Track Global Oncology and Immunology Pipeline
Eli Lilly and Company has entered its seventh strategic collaboration with Innovent Biologics to develop new oncology and immunology therapies. This agreement...
🟢 LLY is trading 4% up today on strong Q4 earnings and upbeat 2026 guidance
LLY is trading at $1061.76 (+4.01%) in pre-market, rebounding sharply from yesterday's drop following the release of its Q4 2025 financial results. • Revenue...
🔴 LLY is trading 5.80% down today amid a broad market sell-off and recession fears
LLY is trading at $1042.89 (-5.80%) today, caught in a broader market sell-off driven by recession fears and weak labor data. • The stock's decline follows a...
🔴 LLY is trading 5.2% down today on profit-taking after a massive post-earnings rally
LLY is trading at $1,049.37 (-5.2%) as investors lock in gains following a +10.3% surge driven by blowout Q4 earnings and strong future guidance. • The...
🔴 LLY is trading 4.4% down today amid broader market weakness and tech rotation
LLY is trading at $1058 (-4.44%) in pre-market, pulling back from recent highs as broader market indices face pressure from hawkish Fed concerns and a rotation...
Eli Lilly's fourth quarter 2025 revenue surged 43% to $19.3 billion, driven by blockbuster sales of Mounjaro and Zepbound.
Eli Lilly reported fourth quarter 2025 revenue of $19.3 billion, a 43% increase year-over-year, driven by strong volume growth. Non-GAAP earnings per share...
FDA Extends Review Timeline for Eli Lilly's Oral Obesity Drug Orforglipron
The U.S. Food and Drug Administration (FDA) extended the review period for Eli Lilly's oral GLP-1 weight-loss candidate, orforglipron. The new expected...